
COPD clinical management guideline - ADULTS

ASSESS PATIENT MOTIVATION, PROVIDE ADVICE, OFFER TREATMENT AND SUPPORT TO STOP SMOKING AT ALL STAGES



Advanced directives or palliative care required

One or more hospital admissions and not known to a supporting specialist service Symptoms disproportionate to lung function deficit Pulmonary rehabilitation required (if not available in primary care) Rapidly progressive course of disease (decline in FEV1, worsening breathlessness, decreased exercise tolerance, unintentional weight loss)

 \checkmark denotes newly licensed medicines or devices intensively monitored by the MHRA. Report ALL suspected adverse reactions via Yellow Card Scheme LABA = Long-acting β_2 agonist, LAMA= Long-acting muscarinic antagonist, ICS=Inhaled Corticosteroid Use For full prescribing information please refer to current BNF / manufacturers information - SPC spacer device with MDI. Further copies of this guideline available from NHS I Medicines Management Team 2020 75271197/1163 Reference: www.nice.org.uk. NICE Clinical Guideline 101 June 2010

Updated by NHS Camden & NHS Islington Joint Respiratory Subgroup 01/2011 Review date 01/2014



Diagnosing COPD


Think of diagnosis of COPD for patients who are:

- over 35
- cigarette OR cannabis smokers or ex-smokers
- (>10 pack years)
- have any of these symptoms:
- exertional breathlessness
- chronic cough
- regular sputum production
- frequent winter 'bronchitis'
- wheeze
- and have no clinical features of asthma (see table below)

Exclude other potential diagnoses

- Physical examination (possible cardiac causes, TB, obstructive sleep apnoea, localised wheeze – ? lung cancer)
- Chest X-Ray (TB/ lung cancer)
- Serial peak flow diary (20% or more variation suggests asthma (see below)
- **Bloods** i.e. FBC,ESR,TFT (i.e. anaemia, polycythaemia, Hypothyroidism, TB)

Consider bronchiectasis if large amounts of sputum daily or frequent infections. Refer to local bronchiestasis treatment guidelines



Determine disease severity (see table below)

Ĵ

Start appropriate treatment (see flowchart overleaf)

Ĵ

Reassess diagnosis in view of response to treatment

Reversibility testing is used to exclude asthma, not diagnose COPD Bronchodilator reversibility

Spirometry should be measured before and after an adequate dose of inhaled bronchodilator.

Ideally use nebulised bronchodilator 2.5 - 5 milligrams salbutamol. Alternatively, use inhaled bronchodilator (using high doses via a spacer) 4 puffs x 100 micrograms salbutamol. Measure lung function 15 minutes after β_2 -agonist.

Steroid trial to exclude asthma

Spirometry should be measured before and immediately after an adequate dose of steroid. Use 30 milligrams oral prednisolone (non-EC tablets) daily for 2 weeks.

Spirometry

Spirometry is a near patient test and therefore should be performed in the community. Support is available from the PCT Primary Care Respiratory Nurse Specialists regarding spirometry services, provision and training. (Respiratory nurses: NHS Islington Provider Services Tel: 020 7527 1715)

Pulse oximetry

Essential to assess hypoxia acutely and to assess need for referral for Long Term O_2 therapy (SaO₂ < 92% on air) when stable. During acute exacerbations, aim for saturation of 88-92% pending arterial blood gases or range documented on Patient Specific Protocol (PSP) or oxygen alert card

Clinical features differentiating COPD and asthma (NB Some patients may have features of both asthma and COPD)			
	COPD	Asthma	
Smoker or ex-smoker	Nearly all	Possibly	
Symptoms under age 35	Rare	Common	
Chronic productive cough	Common	Uncommon	
Breathlessness	Persistent and progressive	Variable	
Night-time waking with breathlessness and/or wheeze	Uncommon	Common	
Significant diurnal or day-to- day variability of symptoms	Uncommon	Common	

Reference: www.nice.org.uk NICE Clinical Guideline 101 June 2010

Ensure severity of diagnosis is adequately explained to patients

Gradation of severity of airflow obstruction			
Post- bronchodilator FEV ₁ /FVC	ronchodilator predicted		
<0.7	≥ 80%	Stage 1 – Mild*	
<0.7	50-79%	Stage 2 - Moderate	
<0.7	30-49%	Stage 3 - Severe	
<0.7	< 30%	Stage 4 – Very Severe**	

*Symptoms should be present to diagnose COPD in people with mild airflow obstruction **Or FEV₁ <50% with respiratory failure



COPD Additional Prescribing and Disease Management Information

INHALER PREFERRED PRESCRIBING CHOICES

Short acting ß ₂ -agonist (SABA)	- salbutamol via MDI device and spacer		
Short acting muscarinic antagonist (SAMA)	- ipratropium via MDI device and spacer		
Long acting B ₂ -agonist (LABA)	– formoterol via MDI device ([*] medication) and spacer		
	- salmeterol via MDI device and spacer		
Long acting muscarinic antagonist (LAMA)	- tiotropium via Handihaler [®] device		
ICS +LABA combination inhalers	- suggested products:		
	 Fostair[®] MDI (beclometasone diproprionate/formoterol) 2 		
	inhalations BD (unlicensed) via spacer device		
	Symbicort Turbohaler 200/6 2 inhalations BD <i>(if inspiratory flow</i>)		
	>60L/min)		
	Seretide Accuhaler [®] (fluticasone/salmeterol) 500/50 1 blisters		
	BD (licensed)		
	Seretide Evohaler [®] MDI (fluticasone/salmeterol) 250/25 2		
	inhalations BD (unlicensed) via spacer device		
	initial atoms BB (anneensed) via spacer device		
Where MDI inhalers are prescribed provide a space	cer device and give adequate counselling on inhaler technique and use of		
the spacer			
ICS can be used as a separate inhaler in combina	tion with LABA (separate inhaler)		
Care should be used in issuing repeat prescription	ns to prevent waste. Be mindful of the quantity of doses per inhaler – some		
	opium and formoterol MDIs whereas others are 60-120 inhalations e.g.		
salmeterol, Fostair [®] , Seretide [®] .			
Check SPC for full licensed indications of all media	cines		
Medication counselling points			
Provide a spacer device for patients using MDI inh	nalers and counsel on the use of this device		
	osteroids (800mcg of standard beclometasone daily or equivalent) should be		
Medication counselling points Ensure adequate inhaler technique and review regularly Provide a spacer device for patients using MDI inhalers and counsel on the use of this device Any patient on long-term high dose inhaled corticosteroids (800mcg of standard beclometasone daily or equivalent) should be			

provided with a steroid card

Inhaled therapy prescriptions should only be changed after input to support smoking for current smokers and review of current pattern and technique of inhaler use with further counselling

▼ denotes newly licensed medicines or devices intensively monitored by the MHRA. Report ALL suspected adverse reactions via Yellow Card Scheme www.yellowcard.gov.uk

Smoking Cessation

Offer nicotine replacement therapy (NRT), bupropion or varenicline where appropriate in line with local guidance and consider referral to quit smoking services

Islington stop smoking services can be contacted on 0207 5271234 / 08000939030 or e-mail stopsmoking@islingtonpct.nhs.uk

EXACERBATION MANAGEMENT

Educate patients regarding symptoms of exacerbation and encourage them to report these early for early treatment Exacerbations can be associated with:

- the format breathlessness
- ↑ sputum purulence
- ↑ sputum volume
- ↑ cough

Initial Management of an exacerbation:

- Increase frequency of bronchodilator use
- Oral prednisolone (non-E/C tablets) 30mg daily for 7 to 14 days (unless contraindicated)

• If purulent sputum – consider oral antibiotics (amoxicillin 500 milligrams TDS 7 days or doxycycline 200 milligrams stat then 100milligrams OD for 6 days)

MRC dyspnoea scale: Grade

- 0 No breathlessness
- 1 Not troubled by breathlessness except on strenuous exercise
- 2 Short of breath when hurrying or walking up a slight hill
- 3 Walks slower than contemporaries on level ground because of breathlessness, or has to stop for breath when walking at own pace
- 4 Stops for breath after walking about 100m or after a few minutes on level ground
 - 5 Too breathless to leave the house, or breathless when dressing or undressing

OXYGEN PRESCRIBING

Information for General Practitioners

Step 1	Step 2	Step 3	Step 4	Step 5
Who's recommended oxygen?	What's the indication?	What else is being offered?	How much is needed?	When's the review date?
If oxygen has been requested by a hospital team, they can complete the HOOF & HOCF themselves in liaison with the chest team Patients commenced on oxygen should have an initial assessment by a specialist and ABG checked	Oxygen is prescribed for hypoxaemia to improve survival - not as a treatment for breathlessnessIf the patient's oxygen saturations are above 92% on room air they are unlikely to need oxygen (unless they desaturate on activity)Complete the diagnosis on the HOOF, for example 01=COPD. A full list is on the Air Products website.	Make sure that for anyone receiving oxygen that other treatments have been offered, for example: Smoking cessation Pulmonary rehabilitation Palliative care (where appropriate)	Oxygen is charged at a daily rate. Specify flow rate and how many hours per day for each type of oxygen. LTOT is given at home usually by oxygen concentrator for >=15 hours a day Ambulatory oxygen is to enable those on LTOT to leave the home (or for those who desaturate on activity)	Patients receiving oxygen should be reviewed regularly. Consider auditing your patients on oxygen and discussing their cases with a respiratory consultant or respiratory nurse. If a patient no longer requires oxygen notify Air Products on 0800 373 580 for the equipment to be collected.

HOOF = Home Oxygen Order Form HOCF = Home Oxygen Consent Form ABG = Arterial Blood Gas LTOT = Long Term Oxygen Therapy Emis codes for Oxygen: Home oxygen supply: 6639 LTOT - Long term oxygen therapy: 8776

References

British Thoracic Society Guidelines <u>http://www.brit-thoracic.org.uk/clinical-information.aspx</u> BLF Oxygen Patient Leaflet <u>http://www.lunguk.org/you-and-your-lungs/diagnosis-and-treatment/oxygen</u> NICE Guidance COPD (June 2010) <u>http://guidance.nice.org.uk/CG101</u> Air Products <u>http://www.airproducts.co.uk/homecare/health_authorities/homeOxygenService/SLA.htm</u>



GP REFERRAL	. TO PULMONARY	' REHABILITATION FOR	AN ISLINGTON PATIENT

Islinaton	Community	Pulmonary	Rehabilitation	Service
ISIIIUUU	COMMUNIC	I UIIIUIIAI V	ιτεπαριπτατισπ	

(please see Guidance on reverse)			
	PATIENT'S DE	TAILS	
Patient's name: Address:	DOB:	Date of referral:	
BASIC CLINICAL INFO	RMATION FOR II	NCLUSION IN PR PROGRAMME	
RESPIRATORY DIAGNOSIS: COPD: YES / NO BRONCHIECTASIS: YES / NO ASTHMA: YES / NO		ANY EXCLUSION CRITERIA? (see reverse for guidance) YES / NO	
Spirometry: FEV ₁ :liters	FVC:lite	ers	
MRC breathlessness scale (se	ee reverse for g	guidance): 1 / 2 / 3 / 4 / 5	
SMOKING HISTORY: never /	ex / current		
On oxygen concentrator: YES / NO SaO ₂ on air at rest (if known):%			
RELEVANT MEDICAL HISTORY/ACTIVE PROBLEMS/MEDICATION HISTORY (Please fax EMIS print out with the referral)			
English spoken? Y / N			
Referrer's details:			
I confirm that I have reviewed this patient and that he/she meets inclusion criteria and has no exclusion criteria. Signature:			
Please include GP's name and GP practice details:			
Patient agrees to referral D Patient's signature:		or Verbal consent obtained only:	

MANY THANKS FOR YOUR REFERRAL - Please note that this form must be filled out completely in order to be accepted. We will send you a confirmation of receipt of referral by fax or letter – if this does not happen within a week of referral, please contact 0844 774 6419. Awaiting list can run on a 2 month.

GUIDANCE FOR REFERRAL:

Pulmonary Rehabilitation (PR) is a multidisciplinary programme of care for patients with long-term respiratory conditions. The recent guidelines on the management of COPD published by the National Institute of Clinical Excellence (NICE) and the British Thoracic Society (BTS) recommend that PR should be available to all appropriate patients. The course involves a period of 8 weeks of exercise and education. The PR programme provided by Islington PCT is held at two different venues:

- Bingfield Primary Care Centre, 8 Bingfield Street (off Caledonian Road), N1 0AL, on Monday and Thursdays from 11.00am to 1.00pm
- Holloway Community Health Centre, 11 Hornsey Street, N78GG, Tuesday and Fridays, from 11.00am to 1.00pm.

Inclusion criteria:

- Patient is under the care of an Islington GP
- Confirmed diagnosis of COPD, Bronchiectasis or Chronic Asthma (must include spirometry FEV1 and FVC)
- > Patient is limited by breathlessness or fatigue but not housebound
- > Medical treatment optimised and patient stable at time of referral
- > Patient can exercise independently in a group setting with minimum supervision
- > Able to make his or her own way to the venue (no transport available)
- > Patient is willing to undertake exercises

Obs: Patients on Long term oxygen therapy will be accepted but they must bring their own ambulatory oxygen cylinder

Exclusions from programme:

- > Unstable angina or cardiac disease
- Aortic stenosis
- > Acute Left Ventricular Failure
- > Uncontrolled hypertension or uncontrolled cardiac arrhythmia's
- > Myocardial infarct within 6 weeks of referral
- SaO₂ < 92% on air at rest (if known)</p>
- Patient requires 1:1 physiotherapy (refer to REACH Team)
- Patient has any medical problem that severely restricts exercise or compliance with the programme (eg dementia, arthritis, stroke, wheelchair bound)

MRC breathlessness scale – Please mark HIGHEST POSITIVE RESPONSE on the referral form:

- grade 1 Not troubled by breathlessness except on strenuous activity
- grade 2 Short of breath when hurrying or walking up a slight hill
- grade 3 Walks slower than contemporaries on the level because of breathlessness, or has to stop for breath when walking at own pace
- grade 4 Stops for breath after walking about 100m or after a few minutes on the level.
- grade 5 Too breathless to leave the house OR breathless when dressing or undressing

Patients who attend can expect:

- > To improve their fitness and feel less breathless
- > Have a better understanding of their condition
- > Have an improved confidence in their ability to manage their symptoms

Please, fax or post referral to:

ARTI NHS Islington Ground Floor 338-346 Goswell Road London EC1V 7LQ FAX: 0844 774 6419 PHONE: 020 3316 1111 Arti.centralbooking@nhs.net

<u>CONFIDENTIAL</u>		NHS Islington	
Referra	al for Stop Smoki	ng Support	
This form mus	st be fully completed and returned a	is soon as possible to:	
	partment 🛛 🛛 🐉	Tel: Freephone 0800 093 9030 Admin: 0207 527 1234 Fax: 0207 527 1340	
Client Information: Ple	ease use BLOCK CAPITALS		
Name of Client:			
Date of Birth:	Male 🗖 Female 🗖		
Add1000.			
Telephone/s:	Ema	ail:	
Other requirements? Language support or disability etc? Please state:			
Preferred form of contact? Phone/ Letter/ Email. Please indicate.			
Referred by:	Organisation:		
Address:			
Telephone Number:	Email:		
	NT PRINTED CLINIC AND PHARMAC	Y DETAILS? Yes/ No	
Please contact Stop Smoking admin if you require these.			

I consent to NHS Islington contacting me: signature:

Office use only: Date form received Client Contacted Information sent Staff details Date Notes for Stop smoking staff: